Antimicrobial resistance is often discussed in terms of clinical use or antibiotic stewardship. Yet an increasingly important dimension of the problem lies far upstream of hospitals and pharmacies: in the way antibiotics are manufactured and released into the environment.
Over the past decade, scientific research has progressively documented how antibiotic residues discharged during pharmaceutical production can contribute to the emergence of resistant bacteria in environmental ecosystems. This issue is now gaining prominence in global AMR policy discussions and in industry benchmarking exercises.
Recent international reports published in early 2026 highlight the growing relevance of environmental stewardship in antibiotic manufacturing, placing pharmaceutical production within the broader One Health framework that links human, animal and environmental health.
Environmental pathways of antimicrobial resistance
The environmental dimension of antimicrobial resistance is primarily linked to the release of active pharmaceutical ingredients (APIs) into water systems.
Industrial wastewater from antibiotic production facilities may contain residual concentrations of antimicrobial substances. When these compounds enter rivers, lakes or soil ecosystems, they can exert selective pressure on environmental bacteria, encouraging the development of resistant strains.
While the majority of pharmaceutical manufacturing sites operate under strict environmental regulations, studies conducted over the past decade have identified localized hotspots of antibiotic contamination near certain production clusters.
This evidence has prompted international organizations and regulators to increasingly consider pharmaceutical manufacturing as a relevant node in the AMR ecosystem.
Responsible manufacturing enters the AMR agenda
The 2026 Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation explicitly includes environmental manufacturing practices among the criteria used to evaluate pharmaceutical companies.
The benchmark assesses whether companies implement responsible antibiotic manufacturing standards, including:
- monitoring antibiotic concentrations in wastewater
- applying science-based discharge limits
- auditing environmental practices across the supply chain.
These measures are intended to reduce the risk that antibiotic production itself contributes to the spread of resistance.
The benchmark highlights that some pharmaceutical companies have already adopted industry-led environmental standards, such as the Antimicrobial Resistance Industry Alliance framework for antibiotic discharge limits.
However, implementation remains uneven across the global supply chain, particularly when production involves multiple contract manufacturers and API suppliers.
Source: Access to Medicine Foundation, Antimicrobial Resistance Benchmark 2026.
Supply chain complexity and API production
One of the challenges in addressing environmental AMR risks is the globalized nature of antibiotic manufacturing.
A significant proportion of antibiotic active ingredients is produced in highly specialized manufacturing clusters, often located in Asia, before being formulated into finished medicines in other regions.
This fragmented supply chain can make environmental oversight more complex. Pharmaceutical companies may not directly control every stage of production, particularly when relying on external API suppliers or contract manufacturing organizations (CMOs).
As a result, responsible antibiotic manufacturing increasingly requires supply chain transparency and environmental auditing beyond company-owned facilities.
Industry alliances and voluntary standards have begun to address this issue by promoting shared environmental guidelines across suppliers.
Regulatory momentum and future standards
Regulators and policymakers are also paying increasing attention to the environmental dimension of AMR.
European institutions have already incorporated environmental considerations into broader pharmaceutical policy debates, particularly within the framework of environmental risk assessment for medicinal products.
Although most current regulations focus on environmental risks associated with the use and disposal of medicines, discussions are expanding to include manufacturing emissions and supply chain oversight.
Within the One Health perspective promoted by international organizations such as the World Health Organization, environmental stewardship in pharmaceutical manufacturing is becoming part of the broader strategy to combat antimicrobial resistance globally.
Manufacturing responsibility in the One Health era
For pharmaceutical manufacturers, the growing attention to environmental AMR introduces new strategic considerations.
Antibiotic production is increasingly expected to align with principles that go beyond traditional quality and safety standards. Companies may need to demonstrate:
- environmental monitoring of antibiotic emissions
- transparent supplier management
- alignment with international responsible manufacturing frameworks.
In this context, antibiotic manufacturing is gradually becoming not only a technical and regulatory issue, but also a reputational and strategic dimension of pharmaceutical sustainability.
As the One Health framework continues to shape global health policy, the environmental footprint of antibiotic production is likely to remain an important topic for regulators, investors and public health authorities alike.
Sources
Access to Medicine Foundation. 2026 Antimicrobial Resistance Benchmark
https://accesstomedicinefoundation.org/resource/2026-antimicrobial-resistance-benchmark
EFSA & ECDC. European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food. 2026
https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2026.9887
World Health Organization. Draft updated Global Action Plan on Antimicrobial Resistance 2026–2036
https://apps.who.int/gb/ebwha/pdf_files/EB158/B158_18-en.pdf
